EMERGENT BIOSOLUTIONS INC. Debt Related Commitment Fees and Debt Issuance Costs
EMERGENT BIOSOLUTIONS INC. (EBS) reported Debt Related Commitment Fees and Debt Issuance Costs of -$1.43 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2017-11-03
- 2017-09-30: Debt Related Commitment Fees and Debt Issuance Costs 9 month -$1.43M.
- 2016-09-30: Debt Related Commitment Fees and Debt Issuance Costs 9 month $0.00.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs 9 month |
|---|---|
| 2017-09-30 | -$1.43M 10-Q · filed 2017-11-03 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |